To rapidly scale up the production of green hydrogen and ammonia, India needs a systematic, long-term framework, according to a senior Larsen & Toubro (L&T) official. The company stressed that predictable policies are essential to attract global capital and accelerate the country’s clean energy transition.

L&T Expands Its Hydrogen Portfolio

L&T’s subsidiary is already setting up a green hydrogen plant at Indian Oil Corporation’s Panipat refinery and continues to explore new opportunities in the hydrogen space. Subramanian Sarma, Deputy Managing Director and President of L&T Group, said that demand creation through clear procurement mechanisms for sectors such as refining, fertilizers, steel, and heavy mobility will be crucial. He added that long-term support for early electrolyser manufacturing and green-molecule projects will help address viability challenges in the initial years.

Key Enablers for a Competitive Hydrogen Hub

Sarma noted that simplified access to round-the-clock renewable power, grid connectivity, streamlined approvals, and land access mechanisms will further strengthen India’s competitiveness. He emphasised the need for a stable, transparent, and forward-looking policy architecture. In 2022, L&T announced plans to invest $2.5 billion in green energy over 3–5 years.

Balanced Investment Strategy

According to Sarma, L&T’s capital allocation strategy aligns with long-term global energy trends. While the hydrocarbon EPC business remains strong and profitable, the company continues to invest in digitalisation, modularisation, talent development, and safety systems to boost competitiveness. He said the company aims to build enduring capabilities across green hydrogen, electrolysers, offshore wind components, and grid and storage solutions.

Global Partnerships in Focus

L&T is in discussions with global firms for minority stake partnerships in its green hydrogen and ammonia projects. These companies view India as an emerging hub for green hydrogen and green ammonia manufacturing. L&T also plans to maintain its presence in the core hydrogen EPC business over the medium and long term.

Strategy: Strengthen Hydrocarbons While Growing Green

Sarma said the company’s strategy is two-fold: strengthen its traditional hydrocarbon EPC capabilities while expanding into low-carbon and renewable sectors. These include CCUS, blue and green hydrogen-ammonia, and onshore and offshore wind projects. He added that L&T sees this shift not as a pivot away from hydrocarbons but as a natural transition where both conventional and green solutions coexist.

Building Integrated Clean Energy Ecosystems

L&T is working to integrate clean energy ecosystems that seamlessly combine generation, storage, transmission, and distribution. The company is building capabilities in battery energy storage systems (BESS), pumped storage, and hybrid combinations of solar and wind. In parallel, L&T is investing in advanced forecasting tools, energy management systems, and AI/ML-driven optimisation platforms—technologies that are essential for renewables to handle baseload responsibilities. The company has already launched pilot projects where hybrid generation is paired with battery storage and controlled digitally for grid stability and load shifting.

Strong Growth Outlook in West Asia

L&T expects West Asia to contribute significantly to its international order book over the next three to five years. Sarma said the company anticipates strong growth in both domestic and overseas markets, with faster acceleration in the Gulf region.

Saudi Arabia: A Key Growth Market

As reported by thehindubusinessline.com, Saudi Arabia represents one of L&T’s most promising markets due to large opportunities in hydrocarbons, clean energy, grid systems, and infrastructure. “By 2030, we expect Saudi Arabia to be one of our largest and most consequential markets,” Sarma said, highlighting a strong pipeline of opportunities across traditional and transition-linked sectors.

Biocon Biologics signed a settlement agreement with Amgen Inc., clearing the path for the commercialisation of Denosumab biosimilars in Europe and other international markets. The agreement enables Biocon Biologics to launch its biosimilars Vevzuo and Evfraxy in Europe starting December 2, 2025. The other terms of the settlement remain confidential.

Expanding Access to Key Therapeutic Areas

“This settlement sets the stage for Biocon Biologics to bring our Denosumab biosimilars, Vevzuo and Evfraxy, to patients across Europe and key international markets,” said Shreehas Tambe, CEO & Managing Director of Biocon Biologics. He added, “This follows our settlement in the US in October and further broadens our reach worldwide in the oncology and bone health therapeutic areas, as we work with healthcare systems to expand access to affordable biologics globally.”

Regulatory Approvals and Indications

The European Commission approved both Vevzuo and Evfraxy in July 2025. Vevzuo prevents skeletal-related events in adults with advanced malignancies involving bone. Evfraxy treats osteoporosis in postmenopausal women and in men at increased risk of fractures, among other conditions.

Strengthening Global Biosimilar Presence

As reported by thehindubusinessline.com, the settlement with Amgen complements Biocon Biologics’ earlier US agreement. It strengthens the company’s ability to expand Denosumab biosimilar access globally. It also reinforces Biocon’s commitment to delivering affordable biologics in critical therapeutic areas.

Insolation Green Energy Private Limited, a wholly owned subsidiary of Insolation Energy Ltd., bagged sale orders worth ₹516.05 crore. The company will supply solar photovoltaic (PV) modules for various projects scheduled between 2025 and 2027.

Major Orders Strengthen Utility-Scale Presence

The order pipeline includes two significant components. First, IGEPPL received a ₹357 crore (inclusive of GST) purchase order to supply N-Type Topcon Solar PV Modules to an Independent Power Producer (IPP). This contract strengthens the company’s footprint in the rapidly growing utility-scale solar market.

Additional Orders Under PM KUSUM Scheme

As reported by filingreader.com, in addition, the company secured ₹159.05 crore in purchase orders from multiple entities participating in the PM KUSUM scheme across Andhra Pradesh. These orders reinforce IGEPPL’s role in supporting government-led renewable energy initiatives aimed at boosting solar adoption in rural and agricultural sectors.

India will set up an integrated rare-earth permanent magnet (REPM) manufacturing ecosystem with a budgetary outlay of ₹7,280 crore over seven years. The initiative aims to sharply reduce import dependence and strengthen domestic supply chains for electric mobility, electronics, defence, and aerospace—key sectors that rely on high-performance permanent magnets.

Building 6,000 TPA Domestic Magnet Capacity

The scheme will establish 6,000 tons per annum (TPA) of REPM manufacturing capacity across five units of 1,200 TPA each. Manufacturers will start production within the next two to three years. India currently consumes about 4,000–5,000 TPA of permanent magnets, importing nearly all of them.

Creating India’s First End-to-End Value Chain

For the first time, India will develop the entire value chain—from rare-earth oxide refining to metal, alloy, and sintered magnet manufacturing—within the country. The government will provide capital expenditure support of around 30%, along with production-linked incentives. Total investment from industry is expected to be three times the government’s commitment. India ranks among the world’s top three nations in rare-earth reserves, with 6.9 million tonnes spread across coastal placer sands and hard-rock deposits in multiple states. The programme aligns closely with India’s Critical Minerals Mission and its broader semiconductor manufacturing drive.

Strengthening Strategic and Industrial Capabilities

Industry consultations received strong interest from electronics, EV, steel, medical equipment, and defence manufacturers. India is also collaborating with Japan and Australia on critical minerals and magnet technologies. The scheme is expected to accelerate clean mobility adoption and strengthen India’s sustainability agenda. Shailesh Chandra, President of the Society of Indian Automobile Manufacturers, said the initiative will help reduce carbon emissions. It will also cut dependence on crude oil imports, further enhancing national energy security.

Ensuring High Environmental Standards

Both government and private-sector players—including semiconductor and automotive companies – have expressed interest. Downtoearth.org.in reports that rising domestic demand will drive the scheme to meet India’s needs and boost export capacities in the coming years.

Pharmaceutical exports are expected to maintain healthy growth over the next several years, supported by a massive wave of patent expiries. According to Pharmaceuticals Export Promotion Council (Pharmexcil) Vice-Chairman Bhavin Mehta, innovator drugs worth over $250 billion are set to go off patents by 2030.

“We are going at around 5–6 per cent (data up to September), and I think growth will be sustained because the next five years will see molecules worth almost $250 billion going off patent,” Mehta informed. He added that major global pharmaceutical players are preparing to launch generic versions of these high-value drugs in regulated markets, opening up significant export opportunities for India.

Domestic Growth and Export Opportunities to Drive Industry

In the coming years, the pharmaceutical industry will leverage two strong growth drivers:

*Domestic demand, growing at around 9–11 per cent

*Rising export opportunities from off-patent drugs

Mehta noted that both segments are performing “pretty fine.” India exported pharmaceuticals worth $30.47 billion in 2024–25, and the figure is expected to rise steadily as generics gain global traction.

Easing Concerns in the US Market

Addressing concerns about the US—India’s largest export destination—Mehta said uncertainties have eased significantly. Commitments from major multinational companies such as Eli Lilly and Pfizer to invest in the US and reduce drug prices have provided some stability.

He echoed views shared by several industry leaders. He said President Trump’s earlier warnings about increased tariffs were primarily targeted at innovator drugs, not generics. “Of the total exports we do, around $10–11 billion goes to the US, and 90 to 99 per cent is generics,” Mehta explained. He stressed that the US administration recognises the immense savings—over $300 billion—that Indian generics have delivered to American consumers. Imposing tariffs on generics, he said, would create a “death trap” by sharply increasing healthcare costs. For the next three years, Mehta believes India’s generic drug exports to the US remain “good to go.”

Strengthening Quality Assurance in Cough Syrup Exports

Mehta highlighted improvements in quality assurance following India’s decision to mandate testing of cough syrups prior to export. The move came after reports that contaminated syrups made in India had caused deaths in countries such as Gambia. “Over the last two years, we have been doing this testing…so it is well controlled and well governed,” he said. As reported by thehindubusinessline.com, Mehta added that updates to domestic Good Manufacturing Practices (GMP) will further strengthen overall product quality and bring greater confidence to global buyers.

Wockhardt announced that the United States Food and Drug Administration (US FDA) has accepted its New Drug Application (NDA) for Zaynich, a first-in-class, novel antibiotic. The acceptance comes at a time when the world urgently needs newer antibiotics to combat the growing challenge of antimicrobial resistance (AMR). This global crisis has intensified as existing antibiotics become less effective due to overuse and erratic consumption patterns.

A Historic First for India

According to the company, the NDA—filed on September 30, 2025—marks a historic milestone.
>“This is the first time in history that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the US FDA,” Wockhardt said. The company emphasized that submitting an NDA requires meeting the highest global scientific and regulatory standards, backed by robust clinical data, strong manufacturing capabilities, and stringent compliance across multiple disciplines.

Addressing Critical Unmet Medical Needs

Zaynich has received ‘Fast Track’ designation from the US FDA, reflecting its potential to address urgent and unmet medical needs. The antibiotic works through a novel β-lactam enhancer mechanism. It has demonstrated potent activity against highly resistant Gram-negative pathogens—microbes that cause prolonged hospital stays and high mortality worldwide.

Wockhardt noted that Zaynich has already shown life-saving impact through compassionate use in critically ill patients in India and the United States.

Strong Market Opportunity

During a June 2025 analyst interaction, Wockhardt’s leadership estimated that Zaynich’s addressable market stands at ₹17,000 crore in India. The company also noted it represents a $7-billion opportunity across the United States and Europe. This underscores the drug’s commercial potential alongside its clinical importance.

Reinforcing India’s Innovation Leadership

As reported by thehindubusinessline.com, Wockhardt said the NDA acceptance reaffirms its commitment to developing advanced anti-infective solutions for global healthcare. The achievement highlights what Indian science and innovation can deliver on the world stage. It reinforces the country’s growing position in high-value pharmaceutical research and development.

Japan Suiso Energy, Ltd. (JSE) and Kawasaki Heavy Industries, Ltd. recently held the ground-breaking ceremony for the Kawasaki LH2 Terminal, a commercial-scale liquefied hydrogen hub in Ogishima, Kawasaki City. The terminal marks a major step forward in Japan’s move toward a large-scale hydrogen supply chain.

Central Facility for Japan’s Hydrogen Supply Chain Demonstration

The Kawasaki LH2 Terminal is a core facility under the “Liquefied Hydrogen Supply Chain Commercialization Demonstration” project, funded by the Green Innovation Fund through the New Energy and Industrial Technology Development Organization (NEDO). As the world’s first commercial-scale liquefied hydrogen terminal, it will feature the world’s largest 50,000 m³ hydrogen storage tank. The terminal will also include advanced infrastructure for maritime cargo handling, hydrogen liquefaction, gas supply, and lorry-based distribution. JSE will oversee project management, while a joint venture led by Kawasaki will design and construct the entire facility.

Building a Global-Scale Hydrogen Logistics System

A next-generation liquefied hydrogen carrier—planned for future construction—will hold approximately 40,000 m³, making it one of the largest in the world. Together with the LH2 terminal, it will serve as a critical backbone for Japan’s future international hydrogen supply chain.

Roadmap to 2030 and Beyond

By FY2030, the project aims to begin full-scale operations of both the Kawasaki LH2 Terminal and the new liquefied hydrogen carrier. During this phase, stakeholders will evaluate key commercial criteria, including performance, safety, durability, reliability, economic feasibility, and long-term scalability.

Asahi Kasei, a diversified global manufacturer operating across healthcare, homes, and material sectors, strategically divested Daramic—its lead battery separator business—to Kingswood Capital Management, LP. Hideyuki Yamagishi, Primary Executive Officer of Asahi Kasei Corporation and President of the Material Sector, emphasized, “As we enter a new era for our company, it is critical that we align our resources with areas that will drive future growth,” he said. “This divestiture represents a strategic step that allows Asahi Kasei to evolve its capabilities with high-potential initiatives, such as strengthening our electronics business and expanding our lithium-ion battery separator business in North America, both key drivers of profit growth.” Asahi Kasei originally acquired Daramic in August 2015 through its purchase of Polypore, gaining control of both the lead battery separator business and the Celgard dry-process lithium-ion separator portfolio.

Sharpening Focus on Lithium-Ion Technologies

Moving forward, Asahi Kasei will intensify its focus on the lithium-ion battery separator market. The company plans to strengthen its Hipore wet-process lithium-ion technology through targeted investments, particularly for automotive applications across North America, Japan, and Korea. This approach supports growing demand for electric vehicles and positions the company as a significant player in next-generation energy storage solutions.

Advancing the “Trailblaze Together” Management Plan

Under its three-year medium-term management plan, Trailblaze Together, Asahi Kasei continues to boost capital efficiency and accelerate earnings by converting earlier growth investments into measurable returns. As part of this strategy, the company is executing structural reforms that funnel resources toward its core growth pillars—pharmaceuticals, critical care, overseas homes, and electronics.

As per the press release, recent decisions such as exiting the methyl methacrylate (MMA) monomer and related businesses, along with expanding production capacity for Pimel photosensitive polyimide, underscore the company’s disciplined approach. These actions reinforce Asahi Kasei’s commitment to long-term, sustainable, and profitable growth.

WACKER, in collaboration with Chinese specialty silane producer and JV partner SICO Performance Material, has inaugurated a new Application Development Center (ADC) for organofunctional silanes in Jining, China. This strategic facility aims to accelerate innovation and strengthen WACKER’s specialty silicone business in the region.

Advanced Facility for High-Performance Additives

The 2,300-square-meter center houses several state-of-the-art laboratories dedicated to developing high-performance additives for the plastics, coatings, and adhesives industries. The ADC also serves as a vital interface between research, technical support, and production, enabling seamless integration of development work with SICO’s production and scale-up resources located nearby. The integration allows for the rapid market launch of new products, meeting the growing demand for specialty silanes in China. Investments in the facility total a mid-six-figure euro sum, reflecting WACKER’s long-term commitment to the region.

Focus on High-Margin Specialty Silanes

Tom Koini, President of WACKER’s Silicones business division, stated, “As a provider of innovative silicone specialties, this development center marks a key milestone for our business in China. Our focus is on high-margin specialty silanes, where demand is continuously rising. This investment, together with our partner SICO, strengthens our presence and commitment to the region.”

Specialty silanes, including organofunctional silanes, are used as:

*Adhesion promoters for high-performance adhesives, sealants, and coatings

*Binders for composite materials

*Additives to enhance plastics

These silanes improve the mechanical and chemical properties of products, driving rising demand in high-tech sectors.

Enhancing Innovation Through Collaboration

Kevin Qu, General Manager of SICO Performance Material, emphasized, “We can now pool all of our silane expertise at the ADC. From chemical product properties and supply chain matters to process engineering and market trends, this know-how will help us develop forward-looking innovations for our customers. This marks a new chapter in our joint venture.” The center allows WACKER and SICO to provide enhanced support for customers in developing and marketing innovative products, reinforcing their position as leading specialty silane manufacturers in China.

Broad Applications Across High-Tech Sectors

The ADC focuses on additives, adhesion promoters, and stabilizers based on organofunctional silanes and functional silicone fluids. These specialty silanes enable the formulation of high-quality adhesives, sealants, coatings, and plastics, which are critical in sectors such as:

*Electromobility

*Electronics

*Power engineering

*Telecommunications

*Industrial coatings

As per the press release, experts at the center bring extensive knowledge in production and process engineering, ensuring that innovations are not only scientifically advanced but also scalable for industrial applications.

Laurent Morineaux, head of the Energy & Industrial Business Unit at WACKER’s Silicones division, and Kevin Qu, SICO Performance Material’s General Manager (fourth and fifth from left) were among those who attended the opening of the WACKER SICO Application Development Center in Jining, China. (Source: WACKER).

Granules India inaugurated two advanced Centres of Excellence (CoE) at the Technology Research Park of IIT Hyderabad, strengthening its research and development capabilities in peptides and advanced material sciences.

Ascelis CoE for Peptide Development and Characterisation

The Ascelis Center of Excellence, established under Ascelis Peptides, the CDMO arm of Granules India, will focus on cosmetic, therapeutic, and pharmaceutical peptide development. This marks Ascelis’ first development and characterisation facility in India, equipped to perform primary, secondary, and tertiary structure characterisation.

By bringing advanced analytical and process development capabilities in-house, the facility will collaborate with Granules’ Swiss-based R&D partner, Senn Chemicals. This integration strengthens the group’s global peptide offering and reduces dependence on external partners.

Granules CoE for Particle Engineering

Replacing earlier external and ad-hoc development efforts, this dedicated research platform will:

*Enable first-to-file opportunities

*Enhance formulation performance

*Support the creation of proprietary technologies for regulated markets

The CoE will accelerate innovation in advanced material sciences and reinforce Granules’ position as a technology-driven CDMO.

Leadership Highlights Strategic Impact

“The launch of these Centres of Excellence significantly strengthens our capabilities in peptides and advanced material sciences, areas that will define the next wave of pharmaceutical innovation,” said Krishna Prasad Chigurupati, Chairman and Managing Director, Granules India. “With specialised infrastructure and deep scientific expertise, we are enhancing our CDMO ambitions, accelerating breakthrough development, and building differentiated technologies that elevate our global competitiveness and deliver meaningful value to our partners and patients worldwide,” he added.